We are live on
!
Find out more
ASC
Atalanta Sosnoff Capital Portfolio holdings
AUM
$5.68B
1-Year Est. Return
54.21%
This Fund
S&P 500
This Quarter
Est. Return
+4.42%
1 Year Est. Return
+54.21%
3 Year Est. Return
+205.88%
5 Year Est. Return
+308.89%
10 Year Est. Return
+1,480.72%
AUM
$3B
AUM Growth
-$184M
(-5.8%)
Cap. Flow
-$262M
Cap. Flow
% of AUM
-8.76%
Top 10 Holdings %
Top 10 Hldgs %
31.22%
Holding
130
New
19
Increased
32
Reduced
50
Closed
26
Avg Time Held
5.8
quarters
Top 10 Avg Time Held
2.6
quarters
Top 20 Avg Time Held
2.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$41.6M |
| 2 |
Johnson & Johnson
JNJ
|
+$34.1M |
| 3 |
Procter & Gamble
PG
|
+$28.4M |
| 4 |
Charter Communications
CHTR
|
+$28.2M |
| 5 |
Crown Castle
CCI
|
+$24.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delta Air Lines
DAL
|
+$55M |
| 2 |
Royal Caribbean
RCL
|
+$45.4M |
| 3 |
Boston Scientific
BSX
|
+$37.6M |
| 4 |
Mastercard
MA
|
+$35.2M |
| 5 |
Hewlett Packard
HPE
|
+$30.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 17.64% |
| 2 | Healthcare | 15.49% |
| 3 | Financials | 12.68% |
| 4 | Energy | 10.14% |
| 5 | Technology | 9.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Pfizer
PFE
$156B
| $46.2M | 1.54% |
1,383,589
-50,481
| -4% | -$1.61M |
2013 Q2
12 quarters
|
|
27
Citigroup
C
$216B
| $45.9M | 1.53% |
1,083,733
-262,817
| -20% | -$11.6M |
2013 Q2
12 quarters
|
|
28
CVS Health
CVS
$111B
| $45.6M | 1.52% |
476,440
-25,855
| -5% | -$2.58M |
2013 Q2
12 quarters
|
|
29
Dollar General
DG
$26.3B
| $45.2M | 1.51% |
480,365
-200,747
| -29% | -$17.3M |
2015 Q4
2 quarters
|
|
|
30
Zimmer Biomet
ZBH
$17.5B
| $43M | 1.43% |
+367,779
| New | +$41.6M |
2016 Q2
0 quarters
|
|
31
Wells Fargo
WFC
$246B
| $39.9M | 1.33% |
843,941
-117,697
| -12% | -$5.74M |
2013 Q2
12 quarters
|
|
32
Verizon
VZ
$190B
| $38.2M | 1.28% |
684,172
-297,633
| -30% | -$15.4M |
2016 Q1
1 quarter
|
|
|
33
Boston Scientific
BSX
$61.4B
| $35.9M | 1.2% |
1,535,649
-1,738,640
| -53% | -$37.6M |
2015 Q1
5 quarters
|
|
|
AGN
34
DELISTED
Allergan plc
AGN
| $35.1M | 1.17% |
151,842
-78,267
| -34% | -$18M |
2014 Q4
6 quarters
|
|
35
Bristol-Myers Squibb
BMY
$120B
| $33.5M | 1.12% |
455,918
-28,502
| -6% | -$2.01M |
2015 Q1
5 quarters
|
|
36
FedEx
FDX
$68.4B
| $31.9M | 1.06% |
210,065
+41,468
| +25% | +$6.72M |
2016 Q1
1 quarter
|
|
37
Medtronic
MDT
$113B
| $31.7M | 1.06% |
364,826
-21,535
| -6% | -$1.74M |
2014 Q2
8 quarters
|
|
38
PepsiCo
PEP
$171B
| $31.6M | 1.06% |
298,556
-98,521
| -25% | -$10.2M |
2015 Q4
2 quarters
|
|
39
American International
AIG
$39.3B
| $31.5M | 1.05% |
594,896
-348,616
| -37% | -$19.2M |
2014 Q2
8 quarters
|
|
40
Walt Disney
DIS
$179B
| $31.4M | 1.05% |
320,871
-52,027
| -14% | -$5.2M |
2013 Q2
12 quarters
|
|
|
41
Procter & Gamble
PG
$339B
| $31.1M | 1.04% |
366,903
+345,773
| +1,636% | +$28.4M |
2015 Q3
3 quarters
|
|
|
42
Charter Communications
CHTR
$12.3B
| $30M | 1% |
+131,252
| New | +$28.2M |
2016 Q2
0 quarters
|
|
43
Alibaba
BABA
$276B
| $29.9M | 1% |
376,102
-26,759
| -7% | -$2.09M |
2014 Q4
6 quarters
|
|
|
PXD
44
DELISTED
Pioneer Natural Resource Co.
PXD
| $29.4M | 0.98% |
194,507
-183,979
| -49% | -$28.9M |
2016 Q1
1 quarter
|
|
45
McDonald's
MCD
$165B
| $27.2M | 0.91% |
226,298
+21,381
| +10% | +$2.68M |
2013 Q2
12 quarters
|
|
46
Salesforce
CRM
$189B
| $27M | 0.9% |
340,333
+171,655
| +102% | +$13.5M |
2013 Q2
12 quarters
|
|
|
47
Crown Castle
CCI
$28.8B
| $27M | 0.9% |
+265,919
| New | +$24.1M |
2016 Q2
0 quarters
|
|
48
Synchrony
SYF
$23.4B
| $26.7M | 0.89% |
1,055,364
-59,172
| -5% | -$1.72M |
2016 Q1
1 quarter
|
|
|
CELG
49
DELISTED
Celgene Corp
CELG
| $25.5M | 0.85% |
258,969
-9,515
| -4% | -$984K |
2013 Q2
12 quarters
|
|
50
Merck
MRK
$344B
| $25.1M | 0.84% |
456,465
-36,890
| -7% | -$1.96M |
2013 Q4
10 quarters
|
|
Similar funds
SPPAM
BCM
CIA
JCM
ECM
BPWM
KKRC
DSC
Atalanta Sosnoff Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Atalanta Sosnoff Capital held 130 positions worth $3B, down 5.8% from $3.18B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Atalanta Sosnoff Capital withdrew a net $262M in Q2 2016, closing 26 positions and reducing 50 holdings. Its most notable exit was Royal Caribbean, an estimated $45.4M position sold in full.
By sector, the portfolio is most concentrated in Communication Services at 18% of assets, down from 18% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Atalanta Sosnoff Capital opened a new position in Zimmer Biomet worth $43M.
- Atalanta Sosnoff Capital's largest Q2 2016 buy was Zimmer Biomet: 367,779 shares worth $43M.
- Atalanta Sosnoff Capital added most to Johnson & Johnson in Q2 2016, an estimated $34.1M increase.
- Atalanta Sosnoff Capital's biggest Q2 2016 reduction was Delta Air Lines, cutting an estimated $55M.
- Atalanta Sosnoff Capital fully exited Royal Caribbean in Q2 2016, selling an estimated $45.4M.
- Atalanta Sosnoff Capital's ten largest holdings make up 31% of its $3B portfolio in Q2 2016.
- Atalanta Sosnoff Capital opened 19 new positions and closed 26 in Q2 2016.
- Atalanta Sosnoff Capital's portfolio value fell 5.8% quarter-over-quarter to $3B.
Based on Atalanta Sosnoff Capital's 13F filing for Q2 2016, filed 25 Jul 2016.